Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era

** Revolution Medicines' RVMD.O groundbreaking pancreatic cancer drug, Rasonque, received the U.S. FDA approval on Wednesday

** RVMD shares up 3% at $222 premarket; average rating on stock is "buy" and median PT is $240 - LSEG data

** At least 7 analysts raised PT after the regulatory nod

** H.C. Wainwright ("buy", PT: $280) says the "landmark FDA approval" of Rasonque has "forever changed" the pancreatic cancer treatment landscape

** TD Cowen ("buy") says Rasonque marks the start of a "post-chemo era" in pancreatic cancer, with broad physician discretion under the label potentially expanding patient access

** Evercore ISI ("outperform", PT: $320) calls Rasonque a "transformative/historic" launch, saying the drug's broad label, strong physician enthusiasm and expanded-access patient conversions could fuel a "steep ramp" in uptake, helping sales reach $2.4 billion in 2027

** Jefferies ("buy", PT: $270) calls RVMD "the most important company in oncology today" saying a "fairly broad" label and "no black box and no testing requirement" should support adoption